Cargando…
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study
Background: We investigate the role of family history of cancer (FHC) and diagnosis of metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 immunotherapy. Design: This was a multicenter retrospective study of advanced cancer patients treated with anti-PD-1/PD-L1 immunother...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959456/ https://www.ncbi.nlm.nih.gov/pubmed/32002308 http://dx.doi.org/10.1080/2162402X.2019.1710389 |
| _version_ | 1783487602055184384 |
|---|---|
| author | Cortellini, Alessio Buti, Sebastiano Bersanelli, Melissa Giusti, Raffaele Perrone, Fabiana Di Marino, Pietro Tinari, Nicola De Tursi, Michele Grassadonia, Antonino Cannita, Katia Tessitore, Alessandra Zoratto, Federica Veltri, Enzo Malorgio, Francesco Russano, Marco Anesi, Cecilia Zeppola, Tea Filetti, Marco Marchetti, Paolo Botticelli, Andrea Cappellini, Gian Carlo Antonini De Galitiis, Federica Vitale, Maria Giuseppa Rastelli, Francesca Pergolesi, Federica Berardi, Rossana Rinaldi, Silvia Tudini, Marianna Silva, Rosa Rita Pireddu, Annagrazia Atzori, Francesco Iacono, Daniela Migliorino, Maria Rita Gelibter, Alain Occhipinti, Mario Alberto Martella, Francesco Inno, Alessandro Gori, Stefania Bracarda, Sergio Zannori, Cristina Mosillo, Claudia Parisi, Alessandro Porzio, Giampiero Mallardo, Domenico Fargnoli, Maria Concetta Tiseo, Marcello Santini, Daniele Ascierto, Paolo A Ficorella, Corrado |
| author_facet | Cortellini, Alessio Buti, Sebastiano Bersanelli, Melissa Giusti, Raffaele Perrone, Fabiana Di Marino, Pietro Tinari, Nicola De Tursi, Michele Grassadonia, Antonino Cannita, Katia Tessitore, Alessandra Zoratto, Federica Veltri, Enzo Malorgio, Francesco Russano, Marco Anesi, Cecilia Zeppola, Tea Filetti, Marco Marchetti, Paolo Botticelli, Andrea Cappellini, Gian Carlo Antonini De Galitiis, Federica Vitale, Maria Giuseppa Rastelli, Francesca Pergolesi, Federica Berardi, Rossana Rinaldi, Silvia Tudini, Marianna Silva, Rosa Rita Pireddu, Annagrazia Atzori, Francesco Iacono, Daniela Migliorino, Maria Rita Gelibter, Alain Occhipinti, Mario Alberto Martella, Francesco Inno, Alessandro Gori, Stefania Bracarda, Sergio Zannori, Cristina Mosillo, Claudia Parisi, Alessandro Porzio, Giampiero Mallardo, Domenico Fargnoli, Maria Concetta Tiseo, Marcello Santini, Daniele Ascierto, Paolo A Ficorella, Corrado |
| author_sort | Cortellini, Alessio |
| collection | PubMed |
| description | Background: We investigate the role of family history of cancer (FHC) and diagnosis of metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 immunotherapy. Design: This was a multicenter retrospective study of advanced cancer patients treated with anti-PD-1/PD-L1 immunotherapy. FHC was collected in lineal and collateral lines, and patients were categorized as follows: FHC-high (in case of cancer diagnoses in both the lineal and collateral family lines), FHC-low (in case of cancer diagnoses in only one family line), and FHC-negative. Patients were also categorized according to the diagnosis of MN as follows: MN-high (>2 malignancies), MN-low (two malignancies), and MN-negative. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and incidence of immune-related adverse events (irAEs) of any grade were evaluated. Results: 822 consecutive patients were evaluated. 458 patients (55.7%) were FHC-negative, 289 (35.2%) were FHC-low, and 75 (9.1%) FHC-high, respectively. 29 (3.5%) had a diagnosis of synchronous MN and 94 (11.4%) of metachronous MN. 108 (13.2%) and 15 (1.8%) patients were MN-low and MN-high, respectively. The median follow-up was 15.6 months. No significant differences were found regarding ORR among subgroups. FHC-high patients had a significantly longer PFS (hazard ratio [HR] = 0.69 [95% CI: 0.48–0.97], p = .0379) and OS (HR = 0.61 [95% CI: 0.39–0.93], p = .0210), when compared to FHC-negative patients. FHC-high was confirmed as an independent predictor for PFS and OS at multivariate analysis. No significant differences were found according to MN categories. FHC-high patients had a significantly higher incidence of irAEs of any grade, compared to FHC-negative patients (p = .0012). Conclusions: FHC-high patients seem to benefit more than FHC-negative patients from anti-PD-1/PD-L1 checkpoint inhibitors. |
| format | Online Article Text |
| id | pubmed-6959456 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Taylor & Francis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69594562020-01-30 Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study Cortellini, Alessio Buti, Sebastiano Bersanelli, Melissa Giusti, Raffaele Perrone, Fabiana Di Marino, Pietro Tinari, Nicola De Tursi, Michele Grassadonia, Antonino Cannita, Katia Tessitore, Alessandra Zoratto, Federica Veltri, Enzo Malorgio, Francesco Russano, Marco Anesi, Cecilia Zeppola, Tea Filetti, Marco Marchetti, Paolo Botticelli, Andrea Cappellini, Gian Carlo Antonini De Galitiis, Federica Vitale, Maria Giuseppa Rastelli, Francesca Pergolesi, Federica Berardi, Rossana Rinaldi, Silvia Tudini, Marianna Silva, Rosa Rita Pireddu, Annagrazia Atzori, Francesco Iacono, Daniela Migliorino, Maria Rita Gelibter, Alain Occhipinti, Mario Alberto Martella, Francesco Inno, Alessandro Gori, Stefania Bracarda, Sergio Zannori, Cristina Mosillo, Claudia Parisi, Alessandro Porzio, Giampiero Mallardo, Domenico Fargnoli, Maria Concetta Tiseo, Marcello Santini, Daniele Ascierto, Paolo A Ficorella, Corrado Oncoimmunology Original Research Background: We investigate the role of family history of cancer (FHC) and diagnosis of metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 immunotherapy. Design: This was a multicenter retrospective study of advanced cancer patients treated with anti-PD-1/PD-L1 immunotherapy. FHC was collected in lineal and collateral lines, and patients were categorized as follows: FHC-high (in case of cancer diagnoses in both the lineal and collateral family lines), FHC-low (in case of cancer diagnoses in only one family line), and FHC-negative. Patients were also categorized according to the diagnosis of MN as follows: MN-high (>2 malignancies), MN-low (two malignancies), and MN-negative. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and incidence of immune-related adverse events (irAEs) of any grade were evaluated. Results: 822 consecutive patients were evaluated. 458 patients (55.7%) were FHC-negative, 289 (35.2%) were FHC-low, and 75 (9.1%) FHC-high, respectively. 29 (3.5%) had a diagnosis of synchronous MN and 94 (11.4%) of metachronous MN. 108 (13.2%) and 15 (1.8%) patients were MN-low and MN-high, respectively. The median follow-up was 15.6 months. No significant differences were found regarding ORR among subgroups. FHC-high patients had a significantly longer PFS (hazard ratio [HR] = 0.69 [95% CI: 0.48–0.97], p = .0379) and OS (HR = 0.61 [95% CI: 0.39–0.93], p = .0210), when compared to FHC-negative patients. FHC-high was confirmed as an independent predictor for PFS and OS at multivariate analysis. No significant differences were found according to MN categories. FHC-high patients had a significantly higher incidence of irAEs of any grade, compared to FHC-negative patients (p = .0012). Conclusions: FHC-high patients seem to benefit more than FHC-negative patients from anti-PD-1/PD-L1 checkpoint inhibitors. Taylor & Francis 2020-01-07 /pmc/articles/PMC6959456/ /pubmed/32002308 http://dx.doi.org/10.1080/2162402X.2019.1710389 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Original Research Cortellini, Alessio Buti, Sebastiano Bersanelli, Melissa Giusti, Raffaele Perrone, Fabiana Di Marino, Pietro Tinari, Nicola De Tursi, Michele Grassadonia, Antonino Cannita, Katia Tessitore, Alessandra Zoratto, Federica Veltri, Enzo Malorgio, Francesco Russano, Marco Anesi, Cecilia Zeppola, Tea Filetti, Marco Marchetti, Paolo Botticelli, Andrea Cappellini, Gian Carlo Antonini De Galitiis, Federica Vitale, Maria Giuseppa Rastelli, Francesca Pergolesi, Federica Berardi, Rossana Rinaldi, Silvia Tudini, Marianna Silva, Rosa Rita Pireddu, Annagrazia Atzori, Francesco Iacono, Daniela Migliorino, Maria Rita Gelibter, Alain Occhipinti, Mario Alberto Martella, Francesco Inno, Alessandro Gori, Stefania Bracarda, Sergio Zannori, Cristina Mosillo, Claudia Parisi, Alessandro Porzio, Giampiero Mallardo, Domenico Fargnoli, Maria Concetta Tiseo, Marcello Santini, Daniele Ascierto, Paolo A Ficorella, Corrado Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study |
| title | Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study |
| title_full | Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study |
| title_fullStr | Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study |
| title_full_unstemmed | Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study |
| title_short | Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study |
| title_sort | evaluating the role of family history of cancer and diagnosis of multiple neoplasms in cancer patients receiving pd-1/pd-l1 checkpoint inhibitors: the multicenter fami-l1 study |
| topic | Original Research |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959456/ https://www.ncbi.nlm.nih.gov/pubmed/32002308 http://dx.doi.org/10.1080/2162402X.2019.1710389 |
| work_keys_str_mv | AT cortellinialessio evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT butisebastiano evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT bersanellimelissa evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT giustiraffaele evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT perronefabiana evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT dimarinopietro evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT tinarinicola evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT detursimichele evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT grassadoniaantonino evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT cannitakatia evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT tessitorealessandra evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT zorattofederica evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT veltrienzo evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT malorgiofrancesco evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT russanomarco evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT anesicecilia evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT zeppolatea evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT filettimarco evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT marchettipaolo evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT botticelliandrea evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT cappellinigiancarloantonini evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT degalitiisfederica evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT vitalemariagiuseppa evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT rastellifrancesca evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT pergolesifederica evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT berardirossana evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT rinaldisilvia evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT tudinimarianna evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT silvarosarita evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT piredduannagrazia evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT atzorifrancesco evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT iaconodaniela evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT migliorinomariarita evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT gelibteralain evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT occhipintimarioalberto evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT martellafrancesco evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT innoalessandro evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT goristefania evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT bracardasergio evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT zannoricristina evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT mosilloclaudia evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT parisialessandro evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT porziogiampiero evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT mallardodomenico evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT fargnolimariaconcetta evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT tiseomarcello evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT santinidaniele evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT asciertopaoloa evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study AT ficorellacorrado evaluatingtheroleoffamilyhistoryofcanceranddiagnosisofmultipleneoplasmsincancerpatientsreceivingpd1pdl1checkpointinhibitorsthemulticenterfamil1study |